Etonogestrel and Ethinyl Estradiol Vaginal Ring: Difference between revisions
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
|blackBoxWarningTitle=WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS | |blackBoxWarningTitle=WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS:</span></i> Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. | |blackBoxWarningBody=<i><span style="color:#FF0000;">CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS:</span></i> Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. | ||
|fdaLIADAdult======How to Use | |fdaLIADAdult======How to Use Etonogestrel and Ethinyl Estradiol Vaginal Ring===== | ||
* To achieve maximum contraceptive effectiveness, | * To achieve maximum contraceptive effectiveness, [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring must be used as directed . One [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring is inserted in the vagina. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed. | ||
* The user can choose the insertion position that is most comfortable to her, for example, standing with one leg up, squatting, or lying down. The ring is to be compressed and inserted into the vagina. The exact position of | * The user can choose the insertion position that is most comfortable to her, for example, standing with one leg up, squatting, or lying down. The ring is to be compressed and inserted into the vagina. The exact position of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring inside the vagina is not critical for its function. The vaginal ring must be inserted on the appropriate day and left in place for three consecutive weeks. This means that the ring should be removed three weeks later on the same day of the week as it was inserted and at about the same time. | ||
* | * [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring can be removed by hooking the index finger under the forward rim or by grasping the rim between the index and middle finger and pulling it out. The used ring should be placed in the sachet (foil pouch) and discarded in a waste receptacle out of the reach of children and pets (do not flush in toilet). | ||
* After a one-week break, during which a withdrawal bleed usually occurs, a new ring is inserted on the same day of the week as it was inserted in the previous cycle. The withdrawal bleed usually starts on Day 2-3 after removal of the ring and may not have finished before the next ring is inserted. In order to maintain contraceptive effectiveness, the new ring must be inserted exactly one week after the previous one was removed even if menstrual bleeding has not finished. | * After a one-week break, during which a withdrawal bleed usually occurs, a new ring is inserted on the same day of the week as it was inserted in the previous [[Menstrual cycle|cycle]]. The withdrawal bleed usually starts on Day 2-3 after removal of the ring and may not have finished before the next ring is inserted. In order to maintain [[contraceptive]] effectiveness, the new ring must be inserted exactly one week after the previous one was removed even if menstrual bleeding has not finished. | ||
=====How to Start Using | =====How to Start Using [[Etonogestrel]] and [[Ethinyl Estradiol]] vaginal ring ===== | ||
'''Consider the possibility of ovulation and conception prior to the first use of | '''Consider the possibility of ovulation and conception prior to the first use of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring.''' | ||
* '''No Hormonal Contraceptive Use in the Preceding Cycle:''' The woman should insert | * '''No Hormonal Contraceptive Use in the Preceding Cycle:''' The woman should insert [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring on the first day of her menstrual bleeding. [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring may also be started on Days 2-5 of the woman's cycle, but in this case a barrier method, such as male condoms with spermicide, should be used for the first seven days of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring use in the first [[Menstrual cycle|cycle]]. | ||
* '''Changing From a CHC:''' The woman may switch from her previous CHC on any day, but at the latest on the day following the usual hormone-free interval, if she has been using her hormonal method consistently and correctly, or if it is reasonably certain that she is not pregnant. | * '''Changing From a Combined Hormonal Contraception (CHC):''' The woman may switch from her previous CHC on any day, but at the latest on the day following the usual hormone-free interval, if she has been using her hormonal method consistently and correctly, or if it is reasonably certain that she is not pregnant. | ||
* '''Changing From a Progestin-Only Method (progestin-only pill [POP], Implant, or Injection or a Progestin-Releasing Intrauterine System [IUS]):''' The woman may switch from the POP on any day; instruct her to start using | * '''Changing From a Progestin-Only Method (progestin-only pill [POP], Implant, or Injection or a Progestin-Releasing Intrauterine System [IUS]):''' The woman may switch from the POP on any day; instruct her to start using [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring on the day after she took her last POP. She should switch from an implant or the IUS on the day of its removal, and from an injectable on the day when the next injection would be due. In all of these cases, the woman should use an additional barrier method such as a male condom with spermicide, for the first seven days. | ||
* '''Use after Abortion or Miscarriage:''' The woman may start using | * '''Use after Abortion or Miscarriage:''' The woman may start using [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring within the first five days following a complete first trimester [[abortion]] or [[miscarriage]], and she does not need to use an additional method of [[contraception]]. If use of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring is not started within five days following a first trimester [[abortion]] or [[miscarriage]], the woman should follow the instructions for "No Hormonal Contraceptive Use in the Preceding Cycle". In the meantime, she should be advised to use a non-hormonal contraceptive method. | ||
:* Start | :* Start [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring no earlier than four weeks after a second trimester [[abortion]] or [[miscarriage]], due to the increased risk of [[thromboembolism]]. | ||
* '''Following Childbirth:''' The use of | * '''Following Childbirth:''' The use of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring may be initiated no sooner than four weeks postpartum in women who elect not to breastfeed, due to the increased risk of [[thromboembolism]] in the postpartum period. | ||
:* Advise women who are breastfeeding not to use | :* Advise women who are breastfeeding not to use [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring but to use other forms of [[contraception]] until the child is weaned. | ||
:* If a woman begins using | :* If a woman begins using [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring postpartum, instruct her to use an additional method of contraception, such as male condoms with spermicide, for the first seven days. If she has not yet had a period, consider the possibility of [[ovulation]] and conception occurring prior to initiation of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring. | ||
=====Deviations from the Recommended Regimen===== | =====Deviations from the Recommended Regimen===== | ||
* To prevent loss of contraceptive efficacy, advise women not to deviate from the recommended regimen. | * To prevent loss of contraceptive efficacy, advise women not to deviate from the recommended regimen. [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring should be left in the vagina for a continuous period of three weeks. | ||
* '''Inadvertent Removal or Expulsion:''' | * '''Inadvertent Removal or Expulsion:''' [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring can be accidentally expelled, for example, while removing a tampon, during intercourse, or with straining during a bowel movement. [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring should be left in the vagina for a continuous period of three weeks. If the ring is accidentally expelled and is left outside of the vagina for less than three hours, contraceptive efficacy is not reduced. [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring can be rinsed with cool to lukewarm (not hot) water and reinserted as soon as possible, but at the latest within three hours. If [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring is lost, a new [[vaginal ring]] should be inserted and the regimen should be continued without alteration. | ||
* '''If | * '''If [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring is out of the vagina for more than three continuous hours:''' | ||
:* '''During Weeks 1 and 2:''' Contraceptive efficacy may be reduced. The woman should reinsert the ring as soon as she remembers. A barrier method such as condoms with spermicides must be used until the ring has been used continuously for seven days. | :* '''During Weeks 1 and 2:''' [[Contraceptive]] efficacy may be reduced. The woman should reinsert the ring as soon as she remembers. A [[Contraceptives#Methods|barrier method]] such as condoms with spermicides must be used until the ring has been used continuously for seven days. | ||
:* '''During Week 3:''' The woman should discard that ring. One of the following two options should be chosen: | :* '''During Week 3:''' The woman should discard that ring. One of the following two options should be chosen: | ||
::# Insert a new ring immediately. Inserting a new ring will start the next three-week use period. The woman may not experience a withdrawal bleed from her previous cycle. However, breakthrough spotting or bleeding may occur. | ::# Insert a new ring immediately. Inserting a new ring will start the next three-week use period. The woman may not experience a withdrawal bleed from her previous cycle. However, breakthrough spotting or bleeding may occur. | ||
::# Insert a new ring no later than seven days from the time the previous ring was removed or expelled, during which time she may have a withdrawal bleed. This option should only be chosen if the ring was used continuously for at least seven days prior to inadvertent removal/expulsion. | ::# Insert a new ring no later than seven days from the time the previous ring was removed or expelled, during which time she may have a withdrawal bleed. This option should only be chosen if the ring was used continuously for at least seven days prior to inadvertent removal/expulsion. | ||
:* In either case, a barrier method such as condoms with spermicides must be used until the new ring has been used continuously for seven days. | :* In either case, a barrier method such as condoms with spermicides must be used until the new ring has been used continuously for seven days. | ||
* '''Prolonged Ring-Free Interval:''' If the ring-free interval has been extended beyond one week, consider the possibility of pregnancy, and an additional method of contraception, such as male condoms with spermicide, MUST be used until | * '''Prolonged Ring-Free Interval:''' If the ring-free interval has been extended beyond one week, consider the possibility of pregnancy, and an additional method of [[contraception]], such as male condoms with spermicide, MUST be used until [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring has been used continuously for seven days. | ||
* '''Prolonged Use of | * '''Prolonged Use of [[Etonogestrel]] and [[Ethinyl Estradiol]] Vaginal Ring :''' If [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring has been left in place for up to one extra week (i.e., up to four weeks total), the woman will remain protected. [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring should be removed and the woman should insert a new ring after a one-week ring-free interval. | ||
* If | * If [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring has been left in place for longer than four weeks, instruct the woman to remove the ring, and rule out pregnancy. If pregnancy is ruled out, [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring may be restarted, and an additional method of [[contraception]], such as male condoms with spermicide, must be used until a new [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring has been used continuously for seven days. | ||
* '''Ring Breakage:''' There have been reported cases of | * '''Ring Breakage:''' There have been reported cases of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring disconnecting at the weld joint. This is not expected to affect the contraceptive effectiveness of [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring. In the event of a disconnected ring, vaginal discomfort or expulsion (slipping out) is more likely to occur. If a woman discovers that her [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring has disconnected, she should discard the ring and replace it with a new ring. | ||
=====In the Event of a Missed Menstrual Period===== | =====In the Event of a Missed Menstrual Period===== | ||
# If the woman has not adhered to the prescribed regimen ( | # If the woman has not adhered to the prescribed regimen ([[etonogestrel]] and [[ethinyl estradiol]] vaginal ring has been out of the vagina for more than three hours or the preceding ring-free interval was extended beyond one week), consider the possibility of pregnancy at the time of the first missed period and discontinue [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring use if pregnancy is confirmed. | ||
# If the woman has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. | # If the woman has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. | ||
# If the woman has retained one | # If the woman has retained one [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring for longer than four weeks, rule out pregnancy. | ||
=====Use with Other Vaginal Products===== | =====Use with Other Vaginal Products===== | ||
* | * [[Etonogestrel]] and [[ethinyl estradiol]] vaginal ring may interfere with the correct placement and position of a diaphragm. A diaphragm is therefore not recommended as a back-up method with [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring use. | ||
* Pharmacokinetic data show that the use of tampons has no effect on the systemic absorption of the hormones released by | * Pharmacokinetic data show that the use of tampons has no effect on the systemic absorption of the hormones released by [[etonogestrel]] and [[ethinyl estradiol]] vaginal ring. | ||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Etonogestrel and Ethinyl Estradiol Vaginal Ring in adult patients. | |||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Etonogestrel and Ethinyl Estradiol Vaginal Ring in adult patients. | |||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Etonogestrel and Ethinyl Estradiol Vaginal Ring in pediatric patients. | |||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Etonogestrel and Ethinyl Estradiol Vaginal Ring in pediatric patients. | |||
|contraindications=* Condition 1 | |contraindications=* Condition 1 | ||
* Condition 2 | * Condition 2 |
Revision as of 17:45, 31 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
See full prescribing information for complete Boxed Warning.
CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS: Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke.
|
Overview
Etonogestrel and Ethinyl Estradiol Vaginal Ring is an estrogen and progestin combination that is FDA approved for the {{{indicationType}}} of to prevent pregnancy. There is a Black Box Warning for this drug as shown here. Common adverse reactions include mood disorder, vaginal discharge, vaginitis.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
How to Use Etonogestrel and Ethinyl Estradiol Vaginal Ring
- To achieve maximum contraceptive effectiveness, etonogestrel and ethinyl estradiol vaginal ring must be used as directed . One etonogestrel and ethinyl estradiol vaginal ring is inserted in the vagina. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.
- The user can choose the insertion position that is most comfortable to her, for example, standing with one leg up, squatting, or lying down. The ring is to be compressed and inserted into the vagina. The exact position of etonogestrel and ethinyl estradiol vaginal ring inside the vagina is not critical for its function. The vaginal ring must be inserted on the appropriate day and left in place for three consecutive weeks. This means that the ring should be removed three weeks later on the same day of the week as it was inserted and at about the same time.
- Etonogestrel and ethinyl estradiol vaginal ring can be removed by hooking the index finger under the forward rim or by grasping the rim between the index and middle finger and pulling it out. The used ring should be placed in the sachet (foil pouch) and discarded in a waste receptacle out of the reach of children and pets (do not flush in toilet).
- After a one-week break, during which a withdrawal bleed usually occurs, a new ring is inserted on the same day of the week as it was inserted in the previous cycle. The withdrawal bleed usually starts on Day 2-3 after removal of the ring and may not have finished before the next ring is inserted. In order to maintain contraceptive effectiveness, the new ring must be inserted exactly one week after the previous one was removed even if menstrual bleeding has not finished.
How to Start Using Etonogestrel and Ethinyl Estradiol vaginal ring
Consider the possibility of ovulation and conception prior to the first use of etonogestrel and ethinyl estradiol vaginal ring.
- No Hormonal Contraceptive Use in the Preceding Cycle: The woman should insert etonogestrel and ethinyl estradiol vaginal ring on the first day of her menstrual bleeding. etonogestrel and ethinyl estradiol vaginal ring may also be started on Days 2-5 of the woman's cycle, but in this case a barrier method, such as male condoms with spermicide, should be used for the first seven days of etonogestrel and ethinyl estradiol vaginal ring use in the first cycle.
- Changing From a Combined Hormonal Contraception (CHC): The woman may switch from her previous CHC on any day, but at the latest on the day following the usual hormone-free interval, if she has been using her hormonal method consistently and correctly, or if it is reasonably certain that she is not pregnant.
- Changing From a Progestin-Only Method (progestin-only pill [POP], Implant, or Injection or a Progestin-Releasing Intrauterine System [IUS]): The woman may switch from the POP on any day; instruct her to start using etonogestrel and ethinyl estradiol vaginal ring on the day after she took her last POP. She should switch from an implant or the IUS on the day of its removal, and from an injectable on the day when the next injection would be due. In all of these cases, the woman should use an additional barrier method such as a male condom with spermicide, for the first seven days.
- Use after Abortion or Miscarriage: The woman may start using etonogestrel and ethinyl estradiol vaginal ring within the first five days following a complete first trimester abortion or miscarriage, and she does not need to use an additional method of contraception. If use of etonogestrel and ethinyl estradiol vaginal ring is not started within five days following a first trimester abortion or miscarriage, the woman should follow the instructions for "No Hormonal Contraceptive Use in the Preceding Cycle". In the meantime, she should be advised to use a non-hormonal contraceptive method.
- Start etonogestrel and ethinyl estradiol vaginal ring no earlier than four weeks after a second trimester abortion or miscarriage, due to the increased risk of thromboembolism.
- Following Childbirth: The use of etonogestrel and ethinyl estradiol vaginal ring may be initiated no sooner than four weeks postpartum in women who elect not to breastfeed, due to the increased risk of thromboembolism in the postpartum period.
- Advise women who are breastfeeding not to use etonogestrel and ethinyl estradiol vaginal ring but to use other forms of contraception until the child is weaned.
- If a woman begins using etonogestrel and ethinyl estradiol vaginal ring postpartum, instruct her to use an additional method of contraception, such as male condoms with spermicide, for the first seven days. If she has not yet had a period, consider the possibility of ovulation and conception occurring prior to initiation of etonogestrel and ethinyl estradiol vaginal ring.
Deviations from the Recommended Regimen
- To prevent loss of contraceptive efficacy, advise women not to deviate from the recommended regimen. Etonogestrel and ethinyl estradiol vaginal ring should be left in the vagina for a continuous period of three weeks.
- Inadvertent Removal or Expulsion: Etonogestrel and ethinyl estradiol vaginal ring can be accidentally expelled, for example, while removing a tampon, during intercourse, or with straining during a bowel movement. Etonogestrel and ethinyl estradiol vaginal ring should be left in the vagina for a continuous period of three weeks. If the ring is accidentally expelled and is left outside of the vagina for less than three hours, contraceptive efficacy is not reduced. Etonogestrel and ethinyl estradiol vaginal ring can be rinsed with cool to lukewarm (not hot) water and reinserted as soon as possible, but at the latest within three hours. If etonogestrel and ethinyl estradiol vaginal ring is lost, a new vaginal ring should be inserted and the regimen should be continued without alteration.
- If etonogestrel and ethinyl estradiol vaginal ring is out of the vagina for more than three continuous hours:
- During Weeks 1 and 2: Contraceptive efficacy may be reduced. The woman should reinsert the ring as soon as she remembers. A barrier method such as condoms with spermicides must be used until the ring has been used continuously for seven days.
- During Week 3: The woman should discard that ring. One of the following two options should be chosen:
- Insert a new ring immediately. Inserting a new ring will start the next three-week use period. The woman may not experience a withdrawal bleed from her previous cycle. However, breakthrough spotting or bleeding may occur.
- Insert a new ring no later than seven days from the time the previous ring was removed or expelled, during which time she may have a withdrawal bleed. This option should only be chosen if the ring was used continuously for at least seven days prior to inadvertent removal/expulsion.
- In either case, a barrier method such as condoms with spermicides must be used until the new ring has been used continuously for seven days.
- Prolonged Ring-Free Interval: If the ring-free interval has been extended beyond one week, consider the possibility of pregnancy, and an additional method of contraception, such as male condoms with spermicide, MUST be used until etonogestrel and ethinyl estradiol vaginal ring has been used continuously for seven days.
- Prolonged Use of Etonogestrel and Ethinyl Estradiol Vaginal Ring : If etonogestrel and ethinyl estradiol vaginal ring has been left in place for up to one extra week (i.e., up to four weeks total), the woman will remain protected. Etonogestrel and ethinyl estradiol vaginal ring should be removed and the woman should insert a new ring after a one-week ring-free interval.
- If etonogestrel and ethinyl estradiol vaginal ring has been left in place for longer than four weeks, instruct the woman to remove the ring, and rule out pregnancy. If pregnancy is ruled out, etonogestrel and ethinyl estradiol vaginal ring may be restarted, and an additional method of contraception, such as male condoms with spermicide, must be used until a new etonogestrel and ethinyl estradiol vaginal ring has been used continuously for seven days.
- Ring Breakage: There have been reported cases of etonogestrel and ethinyl estradiol vaginal ring disconnecting at the weld joint. This is not expected to affect the contraceptive effectiveness of etonogestrel and ethinyl estradiol vaginal ring. In the event of a disconnected ring, vaginal discomfort or expulsion (slipping out) is more likely to occur. If a woman discovers that her etonogestrel and ethinyl estradiol vaginal ring has disconnected, she should discard the ring and replace it with a new ring.
In the Event of a Missed Menstrual Period
- If the woman has not adhered to the prescribed regimen (etonogestrel and ethinyl estradiol vaginal ring has been out of the vagina for more than three hours or the preceding ring-free interval was extended beyond one week), consider the possibility of pregnancy at the time of the first missed period and discontinue etonogestrel and ethinyl estradiol vaginal ring use if pregnancy is confirmed.
- If the woman has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.
- If the woman has retained one etonogestrel and ethinyl estradiol vaginal ring for longer than four weeks, rule out pregnancy.
Use with Other Vaginal Products
- Etonogestrel and ethinyl estradiol vaginal ring may interfere with the correct placement and position of a diaphragm. A diaphragm is therefore not recommended as a back-up method with etonogestrel and ethinyl estradiol vaginal ring use.
- Pharmacokinetic data show that the use of tampons has no effect on the systemic absorption of the hormones released by etonogestrel and ethinyl estradiol vaginal ring.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Etonogestrel and Ethinyl Estradiol Vaginal Ring in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Etonogestrel and Ethinyl Estradiol Vaginal Ring in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Etonogestrel and Ethinyl Estradiol Vaginal Ring FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Etonogestrel and Ethinyl Estradiol Vaginal Ring in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Etonogestrel and Ethinyl Estradiol Vaginal Ring in pediatric patients.
Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5
Warnings
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
See full prescribing information for complete Boxed Warning.
CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS: Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke.
|
Conidition 1
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
(Description)
Pregnancy Category (AUS):
(Description)
Labor and Delivery
(Description)
Nursing Mothers
(Description)
Pediatric Use
(Description)
Geriatic Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Females of Reproductive Potential and Males
(Description)
Immunocompromised Patients
(Description)
Others
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
Solution
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Y-Site
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Admixture
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Syringe
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
TPN/TNA
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
Etonogestrel and Ethinyl Estradiol Vaginal Ring
| |
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | ? |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
(Description)
Storage
There is limited information regarding Etonogestrel and Ethinyl Estradiol Vaginal Ring Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Etonogestrel and Ethinyl Estradiol Vaginal Ring |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Etonogestrel and Ethinyl Estradiol Vaginal Ring |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
(Patient Counseling Information)
Precautions with Alcohol
Alcohol-NuvaRing interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Etonogestrel and Ethinyl Estradiol Vaginal Ring Brand Names in the drug label.
Look-Alike Drug Names
- (Paired Confused Name 1a) — (Paired Confused Name 1b)
- (Paired Confused Name 2a) — (Paired Confused Name 2b)
- (Paired Confused Name 3a) — (Paired Confused Name 3b)
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.